Abbott Laboratories stock outperforms competitors despite losses on the day
This was the stock's third consecutive day of losses.
Piper Sandler initiates Abbott Laboratories with "overweight" rating, $131 PT
Piper Sandler initiated coverage on Abbott Laboratories (NYSE:ABT) with an "overweight" rating and a price target of $131 per share. Piper Sandler emphasizes Abbott’s attractive valuation, strong financial outlook,
Abbott Laboratories' Best Segment Just Got Even Better: Is the Stock a Buy?
Abbott Laboratories' (NYSE: ABT) business has been a bit of a roller coaster. The pandemic disrupted its medical device business, but it was later able to smooth out those losses by quickly developing and marketing COVID-19 diagnostic tests.
Abbott Laboratories stock underperforms Wednesday when compared to competitors
The stock's fall snapped a two-day winning streak.
Abbott Laboratories (ABT) Is a Trending Stock: Facts to Know Before Betting on It
Abbott (ABT) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near future.
Abbott Laboratories' (NYSE:ABT) Stock Been Rising: Are Strong Financials Guiding The Market?
Abbott Laboratories' (NYSE:ABT) stock up by 8.7% over the past three months. Since the market usually pay for a company’s long-term financial health, we decided to study the company’s fundamentals to see if they could be influencing the market. Particularly, we will be paying attention to Abbott Laboratories' ROE today.
Wells Fargo Keeps Their Buy Rating on Abbott Laboratories (ABT)
Wells Fargo analyst Larry Biegelsen maintained a Buy rating on Abbott Laboratories (ABT – Research Report) on September 13 and set a
Law4d
Who Got the Work: O'Melveny Set to Defend Abbott Labs in Digital Privacy Class Action
O'Melveny & Myers is defending Abbott Laboratories in a pending class action against the company and two other ...
Abbott launches its first over-the-counter continuous glucose monitor in the U.S.
Abbott Laboratories announced Lingo, its first over-the-counter continuous glucose monitor, is available in the U.S.
Abbott Laboratories' Attractive Valuation Ranks It Among Top Large-Cap MedTech Companies, Says Analyst
Piper Sandler initiates coverage on Abbott with an Overweight rating, citing its diversified business model, strong medtech ...
Piper Sandler Initiates Coverage of Abbott Laboratories (LSE:0Q15) with Overweight Recommendation
Fintel reports that on September 19, 2024, Piper Sandler initiated coverage of Abbott Laboratories ( LSE:0Q15) with a Overweight recommendation. What is the Fund Sentiment?
Abbott Laboratories: Cardiovascular Disease Has Been A Tailwind, But Things Could Change
Cardiovascular disease is rising, and Abbott Laboratories is well-positioned in the CVD treatment space. Read why I'm neutral ...
Buy Rating on Abbott Laboratories: Undervalued with Strong Growth Prospects Despite NEC Litigation
Adam Maeder, an analyst from Piper Sandler, has initiated a new Buy rating on Abbott Laboratories (ABT). Adam Maeder has given his Buy rating ...
The Motley Fool6d
Abbott Laboratories' Best Segment Just Got Even Better: Is the Stock a Buy?
Abbott Laboratories' diabetes care segment recently added new products to its lineup. It should remain one of the company's key growth drivers over the long run. There are other good reasons to ...
Zacks.com on MSN3d
Abbott Stock Hurt by Macroeconomic Issues & FX Headwind
Foreign exchange fluctuation is a major headwind for ABT, as a considerable percentage of its revenues comes from outside the ...